Published On Mar 28, 2024
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs.
For more on this story, please see: https://www.bloomberg.com/news/articl...
show more